Skip to main content
Clinical Trials/DRKS00023773
DRKS00023773
Completed
Not Applicable

ong Term Cardiac Risk in Recovered COVID-19 Patients Evaluated by 123I-mIBG - COVID-19 HERZ MIBG SPECT

niversitätsklinikum Augsburg - Nuklearmedizin0 sites40 target enrollmentMarch 7, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronavirus disease
Sponsor
niversitätsklinikum Augsburg - Nuklearmedizin
Enrollment
40
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2022
End Date
April 14, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Augsburg - Nuklearmedizin

Eligibility Criteria

Inclusion Criteria

  • Persons tested positive for SARS\-CoV\-2 infection by RT\-PCR, in whom COVID\-19 has led to admission or a stay at the university hospital and who already have a negative PCR of a nasopharyngeal swab before study entry.
  • \- Patients aged \>/\= 18 years at the start of the study.
  • \- Patients who are willing and able to understand and follow the study protocol and who have dated and signed an informed consent form.

Exclusion Criteria

  • \- Patients with known previous cardiac disease and/or previous cardiovascular medication of any kind, such as coronary artery disease without or with subsequent revascularisation by PCI or bypass surgery, heart failure, vitiation, cardiac arrhythmias (e.g. atrial fibrillation), high blood pressure.
  • \- Patients with a pacemaker or ICD, or patients undergoing cardioversion.
  • \- Patients with suspected or known significant allergic reaction or anaphylaxis to iodine or iodine\-containing agents.
  • \- Patients with severe non\-cardiac disease associated with significant elevation of plasma catecholamines, including pheochromocytoma.
  • \- Patients with claustrophobia or other conditions that make it impossible to remain supine for up to one hour.
  • \- Patients with renal insufficiency (serum creatinine \>2\.0 mg/dl or GFR \< 30 ml/min).
  • \- Patients who have already participated in a study with ionising radiation within the last 12 months.
  • \- Patients with type I or II diabetes mellitus, with neurological diseases such as Parkinson's disease, multisystem atrophy or atypical Parkinson's syndromes or other diseases which may affect the autonomic nervous system.
  • \- Pregnant or breastfeeding women
  • \- Minors and patients with mental illness or patients who are unable to provide written informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials